Product image of Myrelez L.P. (Lanreotide Acetate) supplied by GNH India

Myrelez L.P.

Active Ingredient:
Lanreotide Acetate
Origin:
EU

Myrelez L.P. (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Myrelez L.P., is a somatostatin analog presented as an injectable formulation for subcutaneous use. It treats acromegaly and neuroendocrine tumors in adult patients.

GNH India supplies Myrelez L.P. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution. Customers benefit from reliable supply chains, temperature‑controlled logistics where required, and responsive technical assistance throughout the product lifecycle.

Manufacturer / TM Owner

Amdipharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lanreotide acetate is a somatostatin analog used to control hormone‑secreting disorders.

  • Acromegaly: reduces excess growth hormone levels and controls disease activity.
  • Neuroendocrine tumors: inhibits tumor‑related hormone secretion and may stabilize disease progression.
  • Carcinoid syndrome: alleviates flushing and diarrhea associated with hormone‑secreting neuroendocrine tumors.

How It Works

  • Lanreotide acetate binds with high affinity to somatostatin receptor subtypes 2 and 5 on target cells. This interaction inhibits adenylate cyclase activity, reducing cyclic AMP formation and suppressing the secretion of growth hormone, insulin, glucagon, and various peptide hormones. The resulting hormonal blockade curtails the pathological effects of hormone‑overproducing tumors and endocrine disorders.

Side Effects

Adverse reactions may occur with lanreotide therapy.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Diarrhea: loose stools occurring shortly after dosing.
  • Nausea: transient feeling of queasiness.
  • Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects

  • Gallbladder disease: cholelithiasis or biliary colic.
  • Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
  • Severe hyperglycemia: marked increase in blood glucose requiring medical intervention.
  • Allergic reactions: rash, urticaria, or anaphylaxis in susceptible individuals.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Glucose monitoring: assess blood sugar levels, particularly in diabetic patients.
  • Gallbladder evaluation: perform baseline imaging if history of biliary disease exists.
  • Cardiac assessment: review cardiac function in patients with known heart conditions.
  • Concomitant medications: review all current drugs for potential additive hormonal effects.
  • Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Lanreotide may interact with other medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid)

  • Insulin or oral hypoglycemics: increased risk of hyperglycemia.
  • Cyclosporine: potential elevation of cyclosporine blood concentrations.
  • Other somatostatin analogs: additive hormonal suppression.

Moderate Interactions (Monitor Closely)

  • Oral contraceptives: possible reduction in contraceptive efficacy.
  • Antiplatelet agents: heightened risk of bleeding due to gastrointestinal effects.
  • Peptide hormone therapies: overlapping mechanisms may require dose adjustments.

Frequently Asked Questions

Myrelez L.P. contains lanreotide acetate, which is prescribed for the management of acromegaly and for controlling hormone secretion in neuroendocrine tumors, including symptoms such as flushing and diarrhea associated with carcinoid syndrome.

Lanreotide acetate binds to somatostatin receptors 2 and 5 on endocrine cells, inhibiting adenylate cyclase activity and reducing cyclic AMP. This suppresses the release of growth hormone, insulin, glucagon, and other peptide hormones, thereby controlling disease‑related hormone excess.

The specific dose and dosing interval of Myrelez L.P. are determined by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. The prescriber will tailor the regimen to each individual case.

Safety data for lanreotide acetate in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Myrelez L.P., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Myrelez L.P. (lanreotide acetate) shares a similar mechanism with other somatostatin analogs such as octreotide, but differences may exist in dosing frequency, formulation stability, and injection volume. Clinicians choose based on patient preference, tolerability, and specific therapeutic goals.

Myrelez L.P. should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability until administration.

Myrelez L.P. is administered by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a healthcare professional or a trained patient following aseptic technique and the prescriber’s instructions.

Serious adverse events include gallbladder disease (such as cholelithiasis), pancreatitis, severe hyperglycemia, and allergic reactions that may progress to anaphylaxis. Patients should be monitored for these conditions and advised to seek immediate medical attention if symptoms arise.

Myrelez L.P. is contraindicated in patients with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is also advised for individuals with uncontrolled diabetes, active gallbladder disease, or severe cardiac conditions, and it should be avoided in pregnancy unless clearly justified.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lanreotide Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT